FDA’s budget in limbo
This article was originally published in The Tan Sheet
Executive Summary
The 109th Congress failed to pass an FY 2007 appropriations for FDA, instead settling on a continuing resolution that expires Feb. 15. The incoming appropriations chairmen - Sen. Robert Byrd (D-W.Va.) and Rep. Dave Obey (D-Wisc.) - plan to scrap the current, Republican appropriations bills (S 3708, HR 5647) in favor of a year-long continuing resolution. The move would effectively freeze the agency's spending at FY 2006 levels until FY 2008 begins. FDA responded by stating that "a full-year continuing resolution presents difficult challenges." The agency added that through Feb. 15, it "will be working with the administration to analyze the impacts of a continuing resolution"...
You may also be interested in...
FDA Will Close Labs As Spending Is Locked At 2006 Levels
FDA plans to close laboratories across the United States, according to a Dec. 6 e-mail message from the Office of Regulatory Affairs
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.